Most Favored Patient Act of 2026
Summary
HR7837, the Most Favored Patient Act of 2026, is a bearish catalyst for major pharmaceutical companies with high Medicare exposure. The bill proposes linking US Medicare drug prices to the lowest global price, directly threatening the US pricing premium that supports current industry margins. The bill is in early legislative stages but represents a credible structural threat to pharmaceutical pricing power.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR7837 proposes linking US Medicare drug prices to the lowest global price, a direct threat to the US pricing premium.
- 2.The bill is in early legislative stages (referred to committee) with no scheduled action; it is a long-term risk, not an immediate catalyst.
- 3.Major pharma companies with high Medicare exposure — $PFE, $MRK, $LLY, $ABBV — would face structural revenue compression if enacted.
- 4.30-day market data shows sector weakness but not yet pricing in the most-favored-nation bill specifically.
Market Implications
The immediate market impact is low given the early legislative stage, but the bill raises the long-term risk premium on US pharma. Real data shows the sector already trading near the lower end of 52-week ranges: PFE at $26.61 (52-week low $21.97), MRK at $110.86 (52-week low $73.31), and ABBV at $210.98 (52-week low $176.57). Sentiment is already cautious due to existing drug pricing negotiations under the Inflation Reduction Act. The most-favored-nation bill adds another layer of downward pressure on long-term revenue visibility for these companies. Investors should monitor whether this bill gains committee traction or is included in broader health legislation, which would increase the probability of advance and trigger more significant sector repricing.
Full Analysis
On March 5, 2026, Rep. Meuser (R-PA) introduced HR7837, the Most Favored Patient Act of 2026. The bill amends the Social Security Act to require the Center for Medicare and Medicaid Innovation to test a model implementing most-favored-nation drug pricing. The bill has been referred to the Committees on Energy and Commerce and Ways and Means. As an introduced bill in early stages, it has no scheduled markup or vote, but its existence establishes a policy marker for future drug pricing reform.
The bill's mechanism is direct: it would require manufacturers to provide access to the most-favored-nation price (the lowest price offered in any other country) to Medicare beneficiaries. The model would run for five years starting January 1, 2029. This is authorization legislation — it does not appropriate funds, but it mandates a pricing model that would reduce government spending on drugs without requiring new appropriations. The CBO would likely score this as deficit-reducing.
The structural impact is clear: US pharmaceutical companies derive the majority of their profits from the US market, where prices are 2-4x higher than in comparable OECD countries. Linking Medicare prices to the lowest global price would directly compress the highest-margin revenue segment for companies like Pfizer ($PFE), Merck ($MRK), Eli Lilly ($LLY), and AbbVie ($ABBV). These companies have the largest Medicare Part B and Part D drug portfolios. Companies with lower US exposure or primarily non-Medicare revenue (such as pure-play biosimilar makers or OTC-heavy companies) would be less affected.
Real market data shows that the pharmaceutical sector has already been under pressure. Over the 30 days ending April 30, 2026, Merck ($MRK) has declined 7.84%, Pfizer ($PFE) has declined 5.27%, and Johnson & Johnson ($JNJ) has declined 6.15%. Eli Lilly ($LLY) is down 0.83% over 30 days but saw a volatile week ending with a 3.18% gain to $912.10. AbbVie ($ABBV) ended the same week up 6.17% at $210.98. These mixed moves suggest the market is not fully pricing in the most-favored-nation threat yet, possibly due to the early legislative stage.
The legislative timeline is long. For this bill to become law, it must pass both the House and Senate and be signed by the President. The bill is currently in the earliest stage: referred to committee. No hearings, markups, or companion Senate bills exist. This will not become law in 2026. The key legislative milestones to watch are: referral to subcommittee, CBO scoring, hearings, and any inclusion in broader health or budget reconciliation bills. Its sponsor, Rep. Meuser, is a relatively junior House member (first elected 2018), not a committee chair, which limits immediate momentum. However, drug pricing remains a bipartisan pain point, and the most-favored-nation concept has been proposed by both parties in different forms.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Mandatory participation in a CMS Innovation Center model that caps Medicare Part B and Part D drug prices to the lowest price available in any OECD country (most-favored-nation price).
Who must act
Specified manufacturers of covered drugs under Medicare Part B and Part D, defined as entities with a rebate agreement under section 1860D-14A of the Social Security Act.
What happens
Revenues from Medicare Part B and Part D covered drugs would be repriced to the lowest global price; for blockbuster drugs with a US premium of 2-4x over international reference prices, per-unit revenue declines of 50-75% are implied for the Medicare population.
Stock impact
Pfizer's US revenue is heavily concentrated in Medicare-covered drugs (e.g., Prevnar family, Eliquis, Xeljanz, Ibrance). The Medicare population represents a large fraction of total US prescription volume. If implemented, Pfizer would face a direct structural decline in its highest-margin US drug revenue stream.
What the bill does
Mandatory participation in a CMS Innovation Center model that caps Medicare Part B and Part D drug prices to the lowest price available in any OECD country (most-favored-nation price).
Who must act
Specified manufacturers of covered drugs under Medicare Part B and Part D, defined as entities with a rebate agreement under section 1860D-14A of the Social Security Act.
What happens
Revenues from Medicare Part B and Part D covered drugs would be repriced to the lowest global price; for blockbuster drugs with a US premium of 2-4x over international reference prices, per-unit revenue declines of 50-75% are implied for the Medicare population.
Stock impact
Merck's top-selling drugs Keytruda (oncology) and Gardasil (vaccines) have significant Medicare exposure. Keytruda alone accounts for over 40% of Merck's total revenue. A forced price cut to the lowest global price would directly compress Merck's highest-margin revenue stream.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Protecting Americans from Unsafe Drugs Act of 2026
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
American Innovation and R&D Competitiveness Act of 2025
Lowering Drug Costs for American Families Act
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
Skinny Labels, Big Savings Act
Access to Pediatric Technologies Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →